Ionis’s Olezarsen Data Meet Multiple Marks In Blockbuster sHTG Indication

 
• By Mandy Jackson
  
Olezarsen showed durability and efficacy across sHTG patient subgroups in Phase III trials (Shutterstock)

More from Scrip

More from Clinical Trials